KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $2.0 billion.

  • Teva Pharmaceutical Industries' Free Cash Flow rose 3994.45% to $2.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.2 billion, marking a year-over-year increase of 2320.92%. This contributed to the annual value of $2.2 billion for FY2025, which is 2320.92% up from last year.
  • According to the latest figures from Q4 2025, Teva Pharmaceutical Industries' Free Cash Flow is $2.0 billion, which was up 3994.45% from $233.0 million recorded in Q3 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Free Cash Flow ranged from a high of $2.1 billion in Q4 2023 and a low of -$555.0 million during Q1 2021
  • For the 5-year period, Teva Pharmaceutical Industries' Free Cash Flow averaged around $353.3 million, with its median value being $168.0 million (2023).
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Free Cash Flow tumbled by 41355.93% in 2021 and then skyrocketed by 522500.0% in 2023.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Free Cash Flow stood at $303.0 million in 2021, then surged by 174.26% to $831.0 million in 2022, then soared by 154.75% to $2.1 billion in 2023, then plummeted by 31.88% to $1.4 billion in 2024, then surged by 39.94% to $2.0 billion in 2025.
  • Its Free Cash Flow stands at $2.0 billion for Q4 2025, versus $233.0 million for Q3 2025 and $131.0 million for Q2 2025.